Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi/GSK Arixtra Adds DVT, Pulmonary Embolism Treatment Indications

This article was originally published in The Pink Sheet Daily

Executive Summary

Expanded indication comes as Sanofi prepares to divest Arixtra to GlaxoSmithKline in connection with its proposed acquisition of Lovenox-maker Aventis.

You may also be interested in...



Phase III Trial For Sanofi Anti-Clotting Drug Halted Due To Excess Bleeding

Sanofi-Aventis’ idraparinux demonstrated noninferiority versus vitamin K antagonists but was associated with more bleeding, according to Lancet article.

Phase III Trial For Sanofi Anti-Clotting Drug Halted Due To Excess Bleeding

Sanofi-Aventis’ idraparinux demonstrated noninferiority versus vitamin K antagonists but was associated with more bleeding, according to Lancet article.

Sanofi Extends Aventis Offer To June 30

The extension would just meet Sanofi’s goal to close the Aventis merger in the second quarter. The European Commission approved sale of Arixtra and Fraxiparine to GlaxoSmithKline May 26; FTC decision on merger is pending.

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel